WHAT YOU NEED TO KNOW Have You Heard? The Coalition Against Patent Abuse (CAPA) is Fighting Against Anti-Competitive Tactics Used by Some Major Pharmaceutical Companies to Keep Competition Out, Prices High. In a mini-series called, “Spot-On Savings,” CAPA outlined how the U.S. Patent and Trademark Office (USPTO), through its inter partes review (IPR) process, can generate […]

Continue Reading

WHAT YOU NEED TO KNOW Recently, Matrix Global Advisors (MGA) released a white paper that highlights how patent thickets increase barriers for American patients to access affordable biosimilar medications and treatments.   “It is no secret that many pharmaceutical companies today utilize loopholes within the patent system to extend their monopolies while expanding their profits. This white […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Releases Statement after AbbVie CEO Testifies Before the House Oversight and Reform Committee on Use of Anti-Competitive Tactics that Keep Drug Prices High: “CAPA applauds the Committee for its continued oversight on specific anti-competitive tactics that some big drug companies have engaged in over recent years. This patent gamesmanship […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System. Part V: IPR & Ulcerative Colitis – Balancing Innovation and Competition Read the full story below: CAPA examined how the IPR process struck down a patent relating to the […]

Continue Reading

WHAT YOU NEED TO KNOW What The Next U.S. Patent and Trademark Office (USPTO) Director Could Mean For Drug Prices: As anticipation builds around who the next USPTO director will be, the Coalition Against Patent Abuse (CAPA) is highlighting the importance of making the right choice to tackle anti-competitive behavior that will help lower drug prices.  […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System.  Part IV: IPR & Heart Disease – Knocking Down Erroneously Extended Patents. Read the full story below: In 2017, the patent for an anti-clotting drug prasugrel, under […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Stresses Importance Of Next USPTO Director – This week, CAPA Executive Director Matthew Lane penned an op-ed in STAT News highlighting the crucial role that the next U.S. Patent and Trademark Office Director will have on reducing drug costs for millions of American patients, many of which are already struggling financially […]

Continue Reading

WHAT YOU NEED TO KNOW We’re two months into the new year and the Coalition Against Patent Abuse (CAPA) is continuing to highlight why Congress should act to address abuses of the U.S. patent system. Many Big Pharma companies regular engage in tactics that can extend government-granted monopolies and illegitimately keep drug prices high for […]

Continue Reading

WHAT YOU NEED TO KNOW CAPA Continues “Spot-On Savings” Mini-Series To Show How The IPR Process Can Generate Savings For Millions Of Patients & The U.S. Healthcare System. Part II: IPR & Zytiga – Competition Matters – Here, CAPA looks at how the IPR proceeding for the prostate cancer medicine Zytiga accelerated patient access to generic […]

Continue Reading

WHAT YOU NEED TO KNOW BY THE NUMBERS – A new Morning Consult poll conducted for the Campaign for Sustainable Rx Pricing (CSRxP) – a member of CAPA – found that Americans overwhelmingly agree that it is time for Congress and the new Administration to reform the U.S. healthcare system to lower costs and put […]

Continue Reading